evipedia.ai
← Back

GHK-Cu for Health & Longevity

Created on 10/30/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

GHK-Cu, a small natural protein fragment that carries copper, is used in skin care and, more recently, injected in longevity-focused clinics. Small studies support a modest cosmetic effect on wrinkles and eyebrow hair; as a wound treatment, a larger trial found no benefit. Claims of whole-body rejuvenation rest on cell and animal work only. Topical use appears well tolerated; injections have no controlled human safety data. (Full Review)

Protocol

Topical serum (trial regimen)
2% serum, twice daily
12 weeks in the eyebrow trial; facial creams were also applied twice daily for 12 weeks
Cosmetic use levels
Below 10 ppm
Typical copper tripeptide-1 concentration in cosmetics, far below the 2% used in the eyebrow trial
Injectable use
No established dose
Route and schedule also not established in human trials; generally injected subcutaneously, without standardized dosing protocols
Time to effect
Facial skin aging appearance
8–12 weeks
When facial trials assessed results; cosmetic change, if any, appears over months
Hair growth
12 weeks
When the eyebrow trial assessed results

Benefits

Contraindications
  • Wilson disease or other copper-storage disorders
  • Active cancer or cancer under treatment
  • Proliferative diabetic retinopathy or other disorders of abnormal vessel growth
  • Pregnancy and breastfeeding
    •
Key Interactions
Theoretical (inferred from mechanism)
  • Copper chelators (penicillamine, trientine)
  • Copper-lowering cancer therapy (tetrathiomolybdate)
  • Copper supplements and copper-containing multivitamins (copper gluconate, copper bisglycinate)
  • Anti-angiogenic drugs (bevacizumab, ranibizumab)
  • Topical vitamin C and oxidizing acne products, over the counter (ascorbic acid serums, benzoyl peroxide)
  • Topical retinoids (tretinoin, retinol)
  • Microneedling and fractional laser
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low:
  • Speculative: Immune reactions and impurities from compounded or research-grade injectables; tumor growth promotion; copper accumulation with repeated systemic dosing
    •

Monitoring

Marker Target Why
Serum copper About 70–140 µg/dL Copper accumulation with systemic use
Ceruloplasmin About 20–35 mg/dL Screens for impaired copper handling before systemic use
ALT About 7–55 U/L Liver is the main copper-clearing organ
Wrinkle depth on standardized photographs No established target; change from the individual's own baseline Expected to change with topical use

Cadence: Topical use: photographs at baseline, 4, 8 and 12 weeks, then every 3–6 months. Systemic use: serum copper, ceruloplasmin and ALT at baseline, at 4 weeks, then every 3 months during courses; use is typically stopped if any value moves outside its reference range.

Qualitative Assessment

  • Skin texture, firmness and fine-line appearance
  • Eyebrow or scalp hair density on standardized photographs
  • Irritation, redness or itching at application or injection sites
  • Speed of healing of minor cuts or procedure sites
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.